The purpose of this column is to highlight and summarize recent key patents in the pharmaceutical arena issued by the US Patent Office in August-September, 2024.
Membrane Encapsulated Nanoparticles and Method of Use;
L. Zhang, C.M. Hu, R.H. Fang, and J. Copp; The Regents of the University of California, US; U.S. Patent # 12,097,290; September 24, 2024.
Nanoparticles have been commonly used in drug delivery systems. In this patent, the technology has been modeled after RBCs (red blood cells). The nanoparticles feature an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane derived from RBCs. The half-life of these nanoparticles in blood circulation in vivo is two to five times the half-life of PEG-coated nanoparticles. The non-cellular material in the core comprises a material selected from PLGA, PLA, PGA, PCL (polycaprolactone), polylysine, or polyglutamic acid. The cellular membrane from white blood cells, platelets, and immune cells can also be used to coat the core nano-particles.
Wireless Electronics Assembly for Injection Devices;
H. Diefenbach; Sanofi, France; U.S. Patent # 12,090,306; September 17, 2024.
A variety of diseases require treatment by injection of a medicament. A prefilled disposable drug pen or auto-injector can be used as a drug delivery device, which needs the replacement of an empty medicament cartridge with a new one for each use. This disclosure is a drug delivery device with wireless capabilities. An electronics assembly for use in a drug delivery device, comprising a processor, a sensor to measure the fill level of a drug container, a wireless module for communicating with external devices, a power module to supply power to the sensor, the processor,r and the wireless module and a memory storing instructions for the processor to perform. The instructions include activating the sensor for the first time interval and determining the change in the fill level of the drug container. When the change in the fill level is detected, the wireless module is activated to enable the external device to pair with the wireless module.
Injectable Sustained-Release Buprenorphine Formulation;
M. Guarnieri; U.S. Patent # 12,090,151; September 17, 2024.
This formulation is referred to as Buprenorphine Lipid Suspension (BLS). It is preferably administered by subcutaneous injection in an amount effective to manage pain from trauma and post-surgical acute pain in humans and animals for a period of one to seven days. It is resistant to diversion by the patient because the buprenorphine cannot be separated from BLS. BLS offers a safe and effective alternative to the current standard of opioid prescribing and reduces the opportunity for diversion and overdosing. The formulation is made by mixing buprenorphine, glyceryl distearate, and glyceryl tristearate dry powders with a liquid medium chain triglyceride (MCT) such as MIGLYOL 812. The buprenorphine-lipid suspension is provided as 0.2 and 20 mg buprenorphine-glyceryl disterates and tristearates per ml of MCT.
Method for Adjusting the Release of Active Agent in a Transdermal Delivery System;
M. Emgenbroich, J.J. Leonhard, and H.M. Wolff; LTS Lohmann Therapie-Systeme AG, Germany; U.S. Patent # 12,070,521; August 27, 2024.
Transdermal drug delivery systems can provide a constant drug delivery rate of up to seven days which is highly desirable. A concentration gradient between the drug concentration in the delivery system and the bloodstream is often used. However, it needs a large amount of drug loading in the delivery system. The current patent describes a system where the mechanism of drug release is independent of the concentration differential. This biphasic system has an inner hydrophilic layer containing rotigotine and polyvinyl pyrrolidone (PVP) as an additive and a hydrophobic outer phase. PVP has a higher affinity for water in the skin than rotigotine and helps as a driving force for the diffusion of rotigotine.
Pharmaceutical Preparation Excellent In Light Stability And Dissolution Property;
N. Hayashi, M. Gomi, and S. Aikawa; Shionogi & Co., Japan; U.S. Patent # 12,064,438; August 20, 2024.
The present invention provides a preparation that is minimally colored through light irradiation and in which a dissolution property of the compound is improved from the preparation. The patent relates to a preparation containing a polycyclic pyridone compound. The compound is coated with a light stabilizing substance and a polymer. The light-stabilizing substance in the coating layer is one or more substances of titanium oxide and talc. Hypromellose is used as the polymer. The solid preparation described is in the form of a tablet.
Zinc Complex, Preparation Thereof and Use Thereof for Therapy of Human and Animal Diseases;
V.E. Nebolsin; Obschestvo S Ogranichennoi Otvetstvennostiyu Z Therapeutics, Russia; U.S. Patent # 12,077,551; September 3, 2024.
The epithelial cell layer prevents penetration of various substances such as allergens and bacteria thereby preventing anti-inflammatory and allergic diseases. Zinc is one of the key trace elements necessary to maintain barrier function. Zinc is an essential component of matrix metalloproteinases that control epithelial remodeling and help in cell growth, wound healing, etc. Gamma-L-glutamyl histamine (GLGH) has anti-viral and anti-stress activities. The current patent describes a method of preparing zinc complexes with GLGH. The zinc complex was used to treat a subject suffering from atopic dermatitis.
Method for Treating Cancer Using Dengue Virus Serotype 1 (DENV-1);
B.W. Lyday; PrimeVax Immuno-Oncology Inc., USA; U.S. Patent # 12,059,443; August 13, 2024.
Dengue virus is unique among viruses as primary infections carry lower mortality than the common cold while also allowing for increased capillary permeability, and cytokine production, among other features. The present patent discloses the composition and methods comprising an effective amount of Dengue virus for the treatment or reduction of cancer. It combines immune cells called stimulatory dendritic cells with the dengue virus to trigger a broader and stronger immune response against resistant cancer cells. Non-lethal Dengue virus strains are also provided for therapeutic purposes. “Dengue virus” includes any serotype of Dengue virus serotypes 1, 2, 3, 4, or 5.
Author Details
Neelam Sharma, MS; Lakshmi Lavanya Kundurthy, BE; and Hemant N. Joshi, Ph.D., MBA* - Tara Innovations, LLC www.tarainnovations.com, *hemantjoshi.tara@gmail.com
Publication Details
This article appeared in American Pharmaceutical Review:Vol. 27, No. 7Nov/Dec 2024Pages: 62-63
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!